A5012718986- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Protein Degradation and Inhibitors
- Hematological disorders and diagnostics
- Hemoglobinopathies and Related Disorders
- Fungal Infections and Studies
- Lung Cancer Treatments and Mutations
- T-cell and Retrovirus Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Central Venous Catheters and Hemodialysis
- Cancer Treatment and Pharmacology
- Nail Diseases and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Antifungal resistance and susceptibility
- Oral health in cancer treatment
- Vascular Tumors and Angiosarcomas
IPO Porto
2013-2024
Instituto Português de Oncologia Francisco Gentil
2015-2024
Administração Regional de Saúde de Lisboa e Vale do Tejo
2023
Hospital Garcia de Orta
2023
Hospital Braga
2022-2023
Instituto Politécnico de Santarém
2023
Centro Hospitalar de Vila Nova de Gaia
2023
Centro Universitário de João Pessoa
2022
Association for the Development of Douro Viticulture
2022
Centro Hospitalar de Lisboa Central
2022
Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, outcomes adult sAML in Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were novo 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related (t-AML, 25%), antecedent...
Real world effectiveness, toxicity and costs analyses from chimeric antigen receptor (CAR)-T cell therapy are of utmost relevance to determine whether how offer patients highly personalized immunotherapy. In this study, we aimed at describing CAR T-cells safety in a Portuguese Comprehensive Cancer Center. We performed retrospective descriptive study adult with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal transformed follicular referred T-cell therapy,...
Abstract Background NUP98 gene rearrangements have been reported in acute myeloid leukemia, giving rise to fusion proteins that seem function as aberrant transcription factors, and are thought be associated with poor prognosis. Findings A patient treatment-related leukemia presented a t(3;11)(p11;p15) the only cytogenetic abnormality. FISH molecular genetic analyses identified class 1 homeobox gene, POU1F1 , located on chromosome 3p11, partner of . In addition, we found harbored an FLT3-ITD...
Most patients with chronic myeloid leukemia (CML) treated tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of who achieved stable and deep molecular response (DMR) can stop therapy without relapsing. However, most information on cessation was obtained from clinical strict recruiting criteria.We evaluated the outcome 25 CML discontinued TKI in our institute real-world practice.Of patients, 76%...
Acute myeloid leukemia (AML) is a heterogeneous disease with poor prognosis and limited treatment strategies. Determining the role of cell-extrinsic regulators leukemic cells vital to gain clinical insights into biology AML. Iron key extrinsic regulator cancer, but its systemic regulation remains poorly explored in To address this question, we studied iron metabolism patients AML at diagnosis mechanisms involved using syngeneic MLL-AF9-induced mouse model. We found that disorder unique...
Since its original description 2 decades ago, posterior reversible encephalopathy syndrome has been reported in children with several predisposing conditions. Epidemiologic data of hematologic malignancies is still scarce. Herein, we describe the clinical and radiologic features along outcome follow-up complicating treatment malignancies. Ten patients a median age 6.3 years were diagnosed syndrome. Six them undergoing chemotherapy remaining 4 at 37, 52, 78, 857 days after allogenic...
Therapy-related acute myeloid leukemia (t-AML) is a rare and almost always fatal late side effect of antineoplastic treatment involving chemotherapy, radiotherapy or the two combined. The present retrospective study intended to characterize t-AML patients that were diagnosed treated in single referral an oncological institution North Portugal. Over past 10 years, 231 cases AML at Portuguese Institute Oncology Porto, which 38 identified. Data regarding patient demographics, primary diagnosis...
Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by sustained neutrophilia and the absence of Philadelphia chromosome or BCR-ABL1 fusion gene. The present study reports case 59-year-old Caucasian female that was referred to Francisco Gentil Portuguese Institute Oncology (Porto, Portugal) with constitutional symptoms (mainly asthenia), marked leukocytosis (51.33×109/l 90% neutrophils), macrocytic anemia splenomegaly. Bone marrow aspiration biopsy...
This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from to CT-P10.LTBFL were randomized (1:1) receive or (375 mg/m2 intravenously; day 1 of 4 7-day cycles). Patients achieving disease control entered 2-year maintenance period. administered every 8 weeks (6 cycles) year 1; all could (every weeks; 6 2....
Abstract Background A relevant role of septins in leukemogenesis has been uncovered by their involvement as fusion partners MLL -related leukemia. Recently, we have established the MLL-SEPT2 gene molecular abnormality subjacent to translocation t(2;11)(q37;q23) therapy-related acute myeloid In this work quantified and SEPT2 expression 58 leukemia patients selected represent major AML genetic subgroups, well all three cases -associated neoplasms so far described literature. Methods...
Hemophagocytic syndrome is a rare and potentially fatal disorder characterized by pathological immune activation associated with primary familial disorder, genetic mutations, or occurring as sporadic condition. The latter can be secondary to infections, malignancies, autoimmune diseases. Clinically, patients present signs of severe inflammation, unremitting fever, cytopenias, spleen enlargement, phagocytosis bone marrow elements, hypertriglyceridemia, hypofibrinogenemia. Increased suspicion...